Aytu BioPharma to Participate in Noble Capital Markets 21st Annual Emerging Growth Equity Conference
-
US says 'took out' Iran base threatening blocked Hormuz oil route
-
Di Giannantonio takes Brazil MotoGP pole ahead of Bezzecchi, Marquez
-
Welbeck scores twice to dent Liverpool's top-five hopes
-
US strikes Iran bases threatening blocked Hormuz oil route
-
Pirovano wins World Cup downhill title, Aicher puts pressure on Shiffrin
-
Doroshchuk wins Ukraine's second world indoor gold, Hodgkinson and Alfred coast
-
K-pop kings BTS stun Seoul in '2.0' comeback concert
-
French prosecutors suspect Musk encouraged deepfakes row to inflate X value
-
Mbappe 100 percent, Bellingham fit, says Real Madrid's Arbeloa
-
Iranians mark Eid as Tehran reports strike on nuclear plant
-
Kenya, Uganda open rail extension burdened by Chinese debt
-
K-pop kings BTS rock Seoul in comeback concert
-
Invincible Japan edge Australia to win Women's Asian Cup
-
Italy's Paris claims first win of season in World Cup downhill finale
-
In Finland, divers learn to explore icy polar waters
-
Dortmund extend injured captain Can's contract
-
Iranians mark Eid as Trump mulls winding down war
-
Matisse's last years cut out -- but not pasted -- at Paris expo
-
BTS fans take over central Seoul for K-pop kings' comeback
-
Star jockey McDonald becomes horse racing's most prolific Group 1 winner
-
Israel strikes Tehran, Beirut as Trump mulls 'winding down' war
-
Pistons top Warriors to clinch NBA playoff berth
-
Tickets to toothbrushes: BTS's money-making machine
-
Top-ranked Alcaraz, Sabalenka win Miami openers
-
After Cuba beckons, Miami entrepreneurs are mostly reluctant to invest in the island
-
Peru's crowded presidential race zeroes in on organized crime
-
Taiwan's Lin to compete in first international event since Paris gender row
-
BTS takes over central Seoul for comeback concert
-
Jury signals tech titans on hook for social media addiction
-
Brumbies mark Slipper record in thriller against Chiefs
-
US jury finds Elon Musk misled Twitter shareholders
-
SMX Establishes a New Framework for Verification and Visibility Across Global Energy Supply Chains
-
Gauff rallies to avance at Miami Open
-
WNBA, players union confirm agreement on 'groundbreaking' labor deal
-
Carrick 'baffled' by inconsistent penalty calls as Man Utd held
-
Trump says considering 'winding down' Iran war but rules out ceasefire
-
Trump mulls 'winding down' Iran war
-
Man Utd held by Bournemouth after Maguire sees red
-
Lens go top of Ligue 1 with handsome Angers win
-
Leipzig pummel Hoffenheim to climb to third
-
Quinn ousts 11th seed Ruud at rain-hit Miami Open
-
Rap group Kneecap says crisis-hit Cuba being 'strangled'
-
Anthony, Jackson nail US double at world indoors
-
Zarco seizes his moment as rain disrupts Brazil MotoGP practice
-
Chuck Norris, roundhouse-kicking action star, dead at 86
-
US newcomer Anthony crowned world indoor sprint king
-
Trump rules out Iran truce as more Marines head to Middle East
-
Costa Rican ex-security minister extradited to US for drug trafficking
-
Trump slams NATO 'cowards' as more Marines head to Middle East
-
Gulf's decades-long strategy of sporting investment rocked by Mideast war
Aytu BioPharma to Participate in Noble Capital Markets 21st Annual Emerging Growth Equity Conference
DENVER, CO / ACCESS Newswire / November 24, 2025 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (Nasdaq:AYTU), a pharmaceutical company focused on advancing innovative medicines for complex central nervous system diseases to improve the quality of life for patients, today announced that its management will participate at NobleCon21 - Noble Capital Markets' 21st Annual Emerging Growth Equity Conference at Florida Atlantic University, Executive Education Complex, in Boca Raton, FL.
Management will be presenting on Wednesday, December 3rd at 10:30 a.m. Eastern time. A high-definition video webcast of the presentation will be available the following day on the Company's website (www.aytubio.com), and as part of a complete catalog of presentations available at Noble Capital Markets' Conference website (www.nobleconference.com) and on Channelchek (www.channelchek.com), the investor portal created by Noble. The webcast will be archived on the Company's website, the NobleCon website and on Channelchek for 90 days following the event.
Management will also be conducting one-on-one meetings at the conference. Investors should contact their Noble representatives, or Robert Blum of Lytham Partners at [email protected], to schedule one-on-one meetings.
About Aytu BioPharma
Aytu is a pharmaceutical company focused on advancing innovative medicines for complex central nervous system diseases to improve the quality of life for patients. The Company's prescription products include EXXUA™ (gepirone) extended-release tablets (see Full Prescribing Information, including Boxed WARNING) for the treatment of major depressive disorder (MDD) and treatments for attention deficit-hyperactivity disorder (ADHD). Aytu is committed to delivering the Company's medications through best-in-class patient access programs that help to enable optimal patient outcomes. For more information, please visit aytubio.com or follow us on LinkedIn.
Contacts for Investors
Ryan Selhorn, Chief Financial Officer
Aytu BioPharma, Inc.
[email protected]
Robert Blum
Lytham Partners
[email protected]
SOURCE: Aytu BioPharma, Inc.
View the original press release on ACCESS Newswire
G.Stevens--AMWN